Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Ethical perspectives on pharmacogenomic profiling in the drug development process

Nature Reviews Drug Discovery volume 1, pages 300–308 (2002)Cite this article

Key Points

  • One goal of using pharmacogenomics in the drug development process is to determine genotype–phenotype correlations for drug responsiveness and adverse events.

  • An ideal future aim of pharmacogenomic profiling in clinical trials is to eventually develop therapies that are customized or tailored to individuals.

  • Although the objectives of pharmacogenomics are attractive, they raise a host of scientific, ethical and social concerns.

  • In anticipation of further scientific evidence for pharmacogenomics-based predictors of drug responsiveness, it is important to examine issues of ethical concern that are related to the use of pharmacogenomic profiling in clinical trials and the drug development process.

  • This paper addresses some of the ethical concerns that are raised by the integration of genotyping into the drug development process from four perspectives: clinical-trial design; subject stratification; some new social risks; and economic issues.

  • Some recommendations for future research, bioethical analysis and policy planning are proposed.

Abstract

Pharmacogenomics, which is a field that encompasses the study of genetic polymorphisms that underlie individual differences in drug response, is rapidly advancing. The potential for the widespread use of pharmacogenomics in the drug development process merits an examination of its fundamental impact on clinical-trial design and practice. This article provides a critical analysis of some of the issues that pertain to pharmacogenomics in the drug development process. In particular, four areas will be discussed: clinical-trial design; subject stratification; some new social risks; and economic concerns. Recommendations are offered for addressing the issues that are discussed and anticipating the regulatory needs for pharmacogenomics-based trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: An ultimate clinical goal of pharmacogenomics.

Similar content being viewed by others

References

  1. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).

    Article  CAS  Google Scholar 

  2. Rioux, P. P. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am. J. Health Syst. Pharm. 57, 887–898 (2000).

    Article  CAS  Google Scholar 

  3. McLeod, H. L. & Evans, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41, 101–121 (2001).

    Article  CAS  Google Scholar 

  4. Norton, R. M. Clinical pharmacogenomics: applications in pharmaceutical R & D. Drug Discov. Today 6, 180–185 (2001).This paper provides a good overview of the types of pharmacogenomics trial that are underway at present, and why the industry might view pharmacogenomics as a potentially powerful tool in its armament.

    Article  Google Scholar 

  5. Classen, D. C., Pestotnik, S. L., Evans, R. S. & Lloyd, J. F. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301–306 (1997).

    Article  CAS  Google Scholar 

  6. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).

    Article  CAS  Google Scholar 

  7. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 286, 2270–2279 (2001).This is an important systematic review that gives the reader a good understanding of how genetic polymorphisms might be associated with adverse drug reactions.

    Article  CAS  Google Scholar 

  8. Primohamed, M. & Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298–305 (2001).

    Article  Google Scholar 

  9. Persidis, A. Pharmacogenomics. Nature Biotechnol. 18, IT40–IT42 (2000).

    Google Scholar 

  10. Arledge, T., Freeman, A., Arbuckle, J., Mosteller, M. & Manasco, P. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience. Drug Metab. Rev. 32, 387–394 (2000).

    Article  CAS  Google Scholar 

  11. Furuta, T. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69, 158–168 (2001).

    Article  CAS  Google Scholar 

  12. Lessard, E. et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9, 435–443 (1999).

    Article  CAS  Google Scholar 

  13. Drazen, J. M. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).

    Article  CAS  Google Scholar 

  14. Israel, E. et al. Effect of polymorphism of the β(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 124, 183–186 (2001).

    Article  CAS  Google Scholar 

  15. Poirier, J. et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 12260–12264 (1995).

    Article  CAS  Google Scholar 

  16. Richard, F. et al. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349, 539–540 (1997).

    Article  CAS  Google Scholar 

  17. Rigaud, S. et al. The apolipoprotein E4 allele and the response to tacrine therapy in Alzheimer's disease. Eur. J. Neurol. 7, 255–258 (2000).

    Article  CAS  Google Scholar 

  18. Arranz, M. et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281–282 (1995).

    Article  CAS  Google Scholar 

  19. Masellis, M. et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacol. 19, 123–132 (1998).

    Article  CAS  Google Scholar 

  20. Joober, R. et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psych. Neurosci. 24, 141–146 (1999).

    CAS  Google Scholar 

  21. Kuivenhoven, J. A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl. J. Med. 338, 86–93 (1998).

    Article  CAS  Google Scholar 

  22. Drazen, J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).

    Article  CAS  Google Scholar 

  23. World Health Organization. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetics Services <www.who.int/ncd/hgn/hgnethic.htm> (1997).

  24. Holtzman, N. A. & Watson, M. S. (eds) Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing (National Institutes of Health – Department of Energy Working Group on Ethical, Legal and Social Implications of Human Genome Research Task Force on Genetic Testing, Washington DC, 1997).

    Google Scholar 

  25. Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT (2000).

  26. Robertson, J. A. Consent and privacy in pharmacogenetic testing. Nature Genet. 28, 207–209 (2001).This paper provides an overview of some of the consent and privacy issues that could potentially be ethically challenging once pharmacogenetics is used routinely in clinical practice.

    Article  CAS  Google Scholar 

  27. Issa, A. M. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol. Sci. 21, 247–250 (2000).

    Article  CAS  Google Scholar 

  28. Title 45, US Code of Federal Regulations (CFR), part 46. Protection of human subjects. 45CFR46.111(a)(1) <http://ohrp.osophs.dhhs.gov/>.

  29. Friedman, L. M., Furberg, C. D. & DeMets, D. L. Fundamentals of Clinical Trials (Wright, Boston, 1996).

    Google Scholar 

  30. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva, 1993).

  31. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. A Report by a Working Group of the Three Federal Funding councils: Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada (1998).

  32. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA General Assembly Helsinki, Finland, 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland (2000).

  33. Emmanuel, E., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701–2711 (2000).

    Article  Google Scholar 

  34. Murphy, M. P. et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrolment of a Phase III clinical trial. Pharmacogenetics 10, 583–590 (2000).

    Article  CAS  Google Scholar 

  35. Weber, W. W. Pharmacogenetics (Oxford Univ. Press, New York, 1997).

    Google Scholar 

  36. March, R. Pharmacogenomics: the genomics of drug response. Yeast 17, 16–21 (2000).

    Article  CAS  Google Scholar 

  37. Silverman, E. K. & Palmer, L. J. Case–control association studies for the genetics of complex respiratory diseases. Am. J. Respir. Cell. Mol. Biol. 22, 645–648 (2000).

    Article  CAS  Google Scholar 

  38. Bird, T. D., Jarvik, G. P. & Wood, N. W. Genetic association studies: genes in search of diseases. Neurology 57, 1153–1154 (2001).

    Article  CAS  Google Scholar 

  39. Roden, D. M. & George, A. L. The genetic basis of variability in drug responses. Nature Rev. Drug Discov. 1, 37–44 (2002).

    Article  CAS  Google Scholar 

  40. McCarthy, J. J. & Hilfiker, R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nature Biotechnol. 18, 505–508 (2000).

    Article  CAS  Google Scholar 

  41. Cardon, L. R., Idury, R. M. & Harris, T. J. R. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10, 503–510 (2000).

    Article  CAS  Google Scholar 

  42. Long, A. D. & Langley, C. H. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 9, 720–731 (1999).

    CAS  Google Scholar 

  43. Blacker, D. 2-Macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 19, 357–360 (1998).

    Article  CAS  Google Scholar 

  44. Dow, D. J. et al. α2-Macroglobulin polymorphism and Alzheimer disease risk in the UK. Nature Genet. 22, 16–17 (1999).

    Article  CAS  Google Scholar 

  45. Rudransingham, V. et al. α2-Macroglobulin gene and Alzheimer disease. Nature Genet. 22, 17–19 (1999).

    Article  Google Scholar 

  46. Rogaeva, E. A. et al. An α2-Macroglobulin insertion–deletion polymorphism in Alzheimer disease. Nature Genet. 22, 19–21 (1999).

    Article  CAS  Google Scholar 

  47. Editorial. Freely associating. Nature Genet. 22, 1–2 (1999).

  48. Butler, D. Epidemiology set to get fast-track treatment. Nature 414, 139 (2001)

    Article  CAS  Google Scholar 

  49. Albert, S. M., Sano, M. & Marder, K. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 49, 38–43 (1997).

    Article  CAS  Google Scholar 

  50. Knopman, D. et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 47, 166–177 (1996).

    Article  CAS  Google Scholar 

  51. Issa, A. M. & Keyserlingk, E. W. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues. Can. J. Psychiatry 45, 917–922 (2000).

    Article  CAS  Google Scholar 

  52. Sterne, J. A. C. Sifting the evidence – what's wrong with significance tests? Br. Med. J. 322, 226–231.

  53. Becker, R. E. Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin. Drug Invest. 21, 727–733 (2001).

    Article  Google Scholar 

  54. Chen, S. et al. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations. Br. J. Clin. Pharmacol. 44, 303–304 (1997).

    CAS  Google Scholar 

  55. Bodenheimer, T. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl. J. Med. 342, 1539–1544 (2000).

    Article  CAS  Google Scholar 

  56. Zhao, H. Y. Family-based association studies. Stat. Methods Med. Res. 9, 563–587 (2000).

    Article  CAS  Google Scholar 

  57. Jorde, L. B. Linkage disequilibrium and the search for complex disease genes. Genome Res. 10, 1435–1444 (2000).

    Article  CAS  Google Scholar 

  58. Cardon, L. R. & Bell, J. L. Association study designs for complex diseases. Nature Rev. Genet. 2, 91–99 (2001).A thorough review that discusses different designs of genetic-association studies and their inherent limitations. Lessons from these studies need to be considered in thinking about the future design of pharmacogenomics trials.

    Article  CAS  Google Scholar 

  59. Regaldo, A. Inventing the pharmacogenomics business. Am. J. Health Syst. Pharm. 56, 40–50 (1999).

    Article  Google Scholar 

  60. Persidis, A. The business of pharmacogenomics. Nature Biotechnol. 16, 209–210 (1998).

    Article  CAS  Google Scholar 

  61. Fogarty, M. Up for adoption: pharmacogenetics and the orphan drug law. HMS Beagle [online] (cited 01 Mar. 02) <http://www.biomednet.com/hmsbeagle/44/op_ed.htm> (1998).

  62. Food and Drug Administration. Miscellaneous provisions relating to the Orphan Drug Act. Food and Drug Administration (cited 01 Mar 02) <htpp://www.fda.gov/opacom/laws/orphandg.htm> (2001).

  63. National Organization for Rare Diseases (NORD). Understanding the Orphan Drug Act (cited 01 Mar 02) <http://www.rarediseases.org/cgi-bin/nord> (2001).

  64. Europarliament. Scientific and Technological Options Assessment. Orphan Drug Status Initiatives in the Different Countries (cited 01 Mar 02) <http://www.europarl.eu.int/home/default_en.htm>.

  65. Moses, H. & Martin, J. B. Academic relationships with industry: a new model for biomedical research. JAMA 285, 933–935 (2001).

    Article  Google Scholar 

  66. Bains, W. The long-term value of genomics companies. J. Chem. Technol. Biotechnol. 75, 883–900 (2000).

    Article  CAS  Google Scholar 

  67. Aronowitz, R. A. Making Sense of Illness: Science, Society and Disease. (Cambridge Univ. Press, Cambridge, UK, 1998).

    Google Scholar 

  68. Todd, J. A. Interpretation of results from genetic studies of multifactorial diseases. Lancet 354 (Suppl. 1), 15–16 (1999).

    Article  Google Scholar 

  69. Patino, C. M. & Martinez, F. D. Interactions between genes and environment in the development of asthma. Allergy 56, 279–286 (2001).

    Article  CAS  Google Scholar 

  70. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Int. Med. 250, 186–200 (2001).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

A.M.I. gratefully acknowledges the support of the Fonds de la recherche en santé du Québec (FRSQ). This paper was written during the author's tenure as a Fellow of Medical Ethics at Harvard Medical School.

Author information

Authors and Affiliations

  1. Clinical Ethics Center, Memorial Medical Center, Southern Illinois University School of Medicine, 701 North First Street, Springfield, 62781-0001, Illinois, USA

    Amalia M. Issa

  2. Division of Medical Ethics, Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, 02115, Massachusetts, USA

    Amalia M. Issa

Authors
  1. Amalia M. Issa
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

DATABASES

LocusLink

ALOX5

APOE

CETP

CYP2C19

CYP2D6

β-fibrinogen

5-HT2A receptor

lipoprotein lipase

α2-macroglobulin

Medscape DrugInfo

amoxicillin

clozapine

montelukast

omeprazole

pravastatin

tacrine

zileuton

OMIM

Alzheimer's disease

schizophrenia

FURTHER INFORMATION

The Drug Information Association's Pharmacogenetics Working Group

FDA

Human Genome Project

InPharm

International Communication Forum in Human Molecular Genetics

National Center for Biotechnology Information dbSNP database

NIH–NIGMS Pharmacogenetics Research Network

Office for Human Research Protections

Office of Orphan Products Development

Pharmaceutical Research and Manufacturers of America

The Pharmacogenetics Knowledge Base

The SNP Consortium

Stanford Genomic Resources

LINKS

Nature Genetics

Glossary

GENETIC POLYMORPHISM

The difference in DNA sequence among individuals, groups or populations. Genetic variations that occur in more than 1% of a population would be considered useful polymorphisms for genetic-linkage analysis.

GENOTYPE

The genetic constitution of an organism, as distinguished from its physical appearance or characteristics (its phenotype).

GENOTYPING

The determination of relevant nucleotide base sequences in each of the two parental chromosomes.

PHENOTYPE

The physical characteristics of an organism or the presence of a disease that might or might not be genetic.

ALLELE

An alternative form of a genetic locus — a single allele for each locus is inherited from each parent.

SINGLE-NUCLEOTIDE POLYMORPHISM

(SNP). The DNA sequence variations that occur when a single nucleotide (A, T, C or G) in the genome sequence is altered.

PENETRANCE

The probability of a gene or genetic trait being expressed. 'Complete' penetrance means that the gene or genes for a trait are expressed in all the population who have the genes. 'Incomplete' penetrance means that the genetic trait is expressed in only part of the population.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Issa, A. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 1, 300–308 (2002). https://doi.org/10.1038/nrd771

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd771

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing